Fabius- Thank you for posting those numbers. The one question I have is why is Astra Zeneca so low? Is it because they are categorized under a branded product and branded Seroquel XR is filtered out od that list? I would expect they still have a very good market share with the branded product.
All that being said, I think everyone should prepare for very poor revenue numbers this Q. It is very hard for me to estimate Seroquel numbers but I think they will be under $0.5M in revenue for IPCI. I think Focalin will be about $1M. So I am estimating current Q to come in between $1-1.5M total revenue for IPCI.
And yes, I think this current unearthing that the Bloomberg numbers talked about on here are way to high explains why last Q was so disappointing.